GET DAILY SIGNALSWhy Is CVS Health (CVS) Stock Down -12.36% Today?
Key Takeaways
- Shares plunged roughly 12.4%, with CVS trading near $80 after closing the prior session at $91.41.
- The drop defied a strong quarter: the company reported third-quarter results that beat estimates and raised full-year guidance, but investors sold the news.
- Primary catalyst: confirmation of a plan to split the company into two publicly traded businesses by 2028, triggering a "sell the news" reaction and concern over execution risk.
- Secondary drivers: weaker 2027 Medicare Advantage star ratings for Aetna, continued 340B reimbursement pressure, and questions around Caremark client retention.
- Broader context: the decline was company-specific, with major equity indices trading higher during the session.
- Explore Price Targets, Earnings, and Forecast pages for deeper data on this ticker.
- Discover how AI-driven trading signals are navigating this volatility on the Trending AI Robots page.
Opening Summary
CVS Health Corporation, one of America's largest integrated healthcare, pharmacy, and health-insurance companies, saw its stock plunge about 12.4% in Wednesday's session, falling from a prior close of $91.41 to roughly $80 as investors digested a dramatic strategic pivot alongside better-than-expected quarterly results. The company's shares came under heavy selling pressure even though management posted third-quarter adjusted earnings that handily beat Wall Street forecasts and raised its full-year outlook. The immediate reason cited by markets was confirmation of a plan to split the business in two, which overshadowed the positive headline numbers and prompted a classic "sell the news" reaction.
Earnings Beat and Raised Guidance
The fundamental picture was, on paper, encouraging. CVS reported third-quarter adjusted earnings per share of $2.09, well above the roughly $1.65 consensus estimate and up from $1.60 a year earlier, while revenue rose 5.4% year over year to about $108.4 billion. The Health Care Benefits segment was a key driver, reflecting continued progress in the company's margin-recovery plan as the medical loss ratio improved. Management also lifted its full-year 2026 adjusted EPS guidance to at least $8.20, up from a prior range of $7.90 to $8.10, and raised its revenue and operating cash flow outlooks.
Despite these beats, the market's focus quickly shifted away from the numbers toward the structural changes the company unveiled at the same time, leaving the earnings-driven pop short-lived.
Corporate Split Announcement
The dominant catalyst for the decline was the confirmation that CVS intends to separate its retail pharmacy operations from its insurance and pharmacy benefit management (PBM) businesses, creating two independently listed companies in a transaction expected to complete in the first half of 2028. One entity, retaining the CVS Health name under CEO David Joyner, would house Aetna, Caremark, Oak Street Health, Signify Health, and the specialty drug business. The second, CVS Pharmacy, would hold the roughly 9,000-store retail network, mail-order pharmacy, and MinuteClinic locations.
The move marks a sharp reversal of the integrated strategy that defined the company's roughly $78 billion acquisition of Aetna in 2018. While investors had initially bid shares higher when split reports first emerged after-hours on Tuesday, the formal confirmation triggered a "sell the news" reversal. Analysts pointed to the multi-year complexity and execution risk of one of the largest corporate separations in U.S. healthcare history as a key reason the rally faded.
Segment Headwinds and Execution Concerns
Beyond the split itself, several underlying pressures weighed on sentiment. Aetna's 2027 Medicare Advantage star ratings reportedly declined, with only about 70% of members in plans rated four stars or higher, down from roughly 81% previously — a development that could translate into hundreds of millions of dollars in foregone bonus payments. Continued margin pressure from the 340B drug-pricing program and lingering questions about Caremark client retention added further caution. These factors, combined with the long runway before the split completes, left investors weighing near-term earnings strength against a more uncertain multi-year transition.
Market Context and Trading Activity
The price action was clearly company-specific rather than macro-driven. While CVS shares slid, major U.S. equity indices traded higher, underscoring that the selloff reflected idiosyncratic news rather than broad market weakness. Trading volume was elevated relative to recent sessions as investors repriced the stock following the earnings release and restructuring announcement. The decline also represented a technical break lower, with shares moving decisively below recent support levels as the stock surrendered the gains built up in the prior session's after-hours speculation.
What Comes Next for CVS
Investors will now watch closely for additional details on the split's structure, the valuation of each entity, and the leadership and capital allocation plans for both companies as the 2028 separation approaches. Near-term attention will center on whether the Health Care Benefits margin recovery continues, how the Medicare Advantage star-rating headwind develops, and whether management can sustain the raised guidance in the face of elevated medical costs. Execution risk around the separation, regulatory scrutiny of PBMs, and ongoing reimbursement pressures remain key uncertainties that could continue to drive volatility in the shares.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing most strongly under current market conditions. Tickeron offers hundreds of these automated bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. For traders seeking to navigate volatile moves like this one with a data-driven, systematic approach, exploring the Trending AI Robots section can be a useful starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CVS in +2.59% Uptrend, advancing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CVS moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 160 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 24 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 48 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.467) is slightly lower than the industry average of (3.359). P/E Ratio (23.929) is within average values for comparable stocks, (126.681). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement